Pharma-Bio Serv, Inc. 10-K/A Report: Key Investor Insights and Potential Share Price Drivers

Overview

Pharma-Bio Serv, Inc. filed its Form 10-K/A (Amendment No. 1) for the fiscal year ended October 31, 2025. This amendment provides updated disclosures required by Items 10-14 of Part III of the original 10-K, as well as Sarbanes-Oxley certifications. The company continues to operate out of Dorado, Puerto Rico, and maintains its business focus as a consulting group servicing pharmaceutical, biotechnology, and related industries.

Key Points from the Report

• Fiscal Year End: October 31, 2025. The amendment was filed on February 27, 2026.
• Common Stock Outstanding: 22,904,492 shares.
• Market Value of Public Float: Based on the closing price as of April 30, 2025, the aggregate market value of common stock held by non-affiliates is disclosed, though the exact value is not provided in the visible portion. This metric is critical for investors assessing liquidity and company valuation.
• Reporting Status: The company confirms full compliance with SEC reporting requirements, including all filings and Interactive Data submissions.
• Filer Status: Pharma-Bio Serv is classified as a “Smaller Reporting Company” and “Non-Accelerated Filer,” and is not an “Emerging Growth Company” or a “Well-Known Seasoned Issuer.”
• Internal Controls: The company did not file a report on or attestation to its management’s assessment of internal control effectiveness under Section 404(b) of Sarbanes-Oxley, indicating it is not required to do so as a smaller reporting company.
• Legal Proceedings: Management states, “To the best of our knowledge, none of our directors or executive officers…has been involved during the past ten years in any legal proceedings required to be disclosed.” This is positive for corporate governance and risk assessment.
• Code of Ethics: The company has adopted and recently updated its Code of Ethics, including an Insider Trading Policy, and intends to post updates or waivers on its website. This is important for investor confidence in governance and regulatory compliance.
• Compensation: The summary compensation table is disclosed for executive officers, though detailed figures are not shown in the visible extract. Investors should note compensation structures as they affect both retention and dilution risk.
• Equity Compensation Plans: As of October 31, 2025, there are 1,050,000 shares available for future issuance under equity compensation plans, with a weighted average exercise price of \$0.9108 per share. The 2014 Long-Term Incentive Plan was amended and extended to March 31, 2034, potentially leading to future dilution if exercised.
• Audit Fees: Audit fees for fiscal 2024 and 2025 are disclosed at \$71,490, indicating stable audit costs and no unusual accounting issues.
• Certifications: Sarbanes-Oxley Act Section 302 and 906 certifications are filed by CEO Victor Sanchez and CFO Pedro J. Lasanta, confirming the accuracy and disclosure of all material facts and absence of fraud.

Potentially Price-Sensitive and Shareholder-Relevant Information

• No Material Legal Proceedings or Fraud: The lack of legal proceedings and stated absence of fraud involving management is positive for investor confidence and reduces regulatory risk.
• Equity Plan Changes: The extension of the Long-Term Incentive Plan for an additional ten years and the availability of 1,050,000 shares for issuance could impact future earnings per share through dilution if exercised. Investors should monitor management’s use of equity incentives, as aggressive issuance could affect share value.
• Internal Control Reporting: The company does not provide auditor attestation on internal controls (as permitted for smaller reporting companies). Investors may view this as a risk factor, as external validation of controls is not present.
• Governance Policies: The updated Code of Ethics and Insider Trading Policy, now publicly referenced on the website, enhances transparency and governance standards, which may positively impact investor sentiment.
• Compensation Disclosure: While the actual numbers are not fully visible, the compensation structure and equity awards are significant for evaluating alignment of management incentives with shareholder interests.

Shareholder Alerts

• Potential Dilution: The extended equity compensation plan and available shares for issuance represent potential dilution. Shareholders should monitor subsequent filings for actual awards or exercises.
• Governance Enhancements: The adoption and update of the Code of Ethics, including insider trading policies, is a positive step for compliance and risk mitigation.
• Audit Stability: Consistent audit fees and compliance with SEC reporting requirements indicate operational stability.

Conclusion

The 10-K/A filing by Pharma-Bio Serv, Inc. is primarily an update to governance, compensation, and compliance disclosures. The most price-sensitive aspects for investors are the extension of the equity compensation plan (potential dilution risk), governance improvements, and assurance of no material legal or fraud issues. Investors may also want to monitor executive compensation and future equity issuance for impact on share value.

Disclaimer: This article is based on publicly available SEC filings and is intended for informational purposes only. It does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. The author disclaims any liability for actions taken based on the information herein.

View Pharma-Bio Serv, Inc. Historical chart here